KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:GUD - CA4990531069 - Common Stock
5.97 CAD
-0.01 (-0.17%)
GUD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. While GUD seems to be doing ok healthwise, there are quite some concerns on its profitability. GUD is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
GUD had negative earnings in the past year.
In the past year GUD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
GUD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
GUD's Return On Assets of -0.33% is fine compared to the rest of the industry. GUD outperforms 65.63% of its industry peers.
With a decent Return On Equity value of -0.46%, GUD is doing good in the industry, outperforming 68.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of GUD has declined.
GUD has a Gross Margin (42.49%) which is in line with its industry peers.
GUD's Gross Margin has declined in the last couple of years.
GUD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
GUD has less shares outstanding than it did 1 year ago.
The number of shares outstanding for GUD has been reduced compared to 5 years ago.
Compared to 1 year ago, GUD has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.09 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
GUD has a Altman-Z score of 2.09. This is amongst the best in the industry. GUD outperforms 84.38% of its industry peers.
The Debt to FCF ratio of GUD is 37.42, which is on the high side as it means it would take GUD, 37.42 years of fcf income to pay off all of its debts.
GUD has a Debt to FCF ratio (37.42) which is in line with its industry peers.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GUD (0.11) is better than 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Altman-Z | 2.09 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
A Current Ratio of 2.62 indicates that GUD has no problem at all paying its short term obligations.
GUD has a better Current ratio (2.62) than 68.75% of its industry peers.
GUD has a Quick Ratio of 1.68. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of GUD (1.68) is better than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 93.10% over the past year.
Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
Looking at the last year, GUD shows a quite strong growth in Revenue. The Revenue has grown by 18.70% in the last year.
The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
3.2 Future
Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 55.65% on average per year.
GUD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.50% yearly.
EPS Next Y-382.8%
EPS Next 2Y22.26%
EPS Next 3Y41.41%
EPS Next 5Y55.65%
Revenue Next Year20.19%
Revenue Next 2Y14%
Revenue Next 3Y9.74%
Revenue Next 5Y10.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
GUD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 79.88, the valuation of GUD can be described as expensive.
Based on the Price/Forward Earnings ratio, GUD is valued a bit cheaper than 62.50% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, GUD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 79.88 |
4.2 Price Multiples
GUD's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GUD is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 208.79 | ||
| EV/EBITDA | 12.39 |
4.3 Compensation for Growth
A more expensive valuation may be justified as GUD's earnings are expected to grow with 41.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.26%
EPS Next 3Y41.41%
5. Dividend
5.1 Amount
No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:GUD (12/24/2025, 7:00:00 PM)
5.97
-0.01 (-0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.6%
Inst Owner ChangeN/A
Ins Owners1.87%
Ins Owner ChangeN/A
Market Cap592.76M
Revenue(TTM)413.85M
Net Income(TTM)-3.49M
Analysts78.18
Price Target8.03 (34.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-753.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)-692.08%
EPS beat(4)2
Avg EPS beat(4)-169.96%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)2
Avg EPS beat(8)-354.72%
EPS beat(12)5
Avg EPS beat(12)-190.89%
EPS beat(16)7
Avg EPS beat(16)-395.3%
Revenue beat(2)2
Avg Revenue beat(2)11.78%
Min Revenue beat(2)11.06%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)8.38%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)7
Avg Revenue beat(8)5.34%
Revenue beat(12)11
Avg Revenue beat(12)8.81%
Revenue beat(16)14
Avg Revenue beat(16)8.72%
PT rev (1m)0.92%
PT rev (3m)0.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-250%
EPS NY rev (1m)-22.81%
EPS NY rev (3m)-22.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.51%
Revenue NY rev (1m)4.68%
Revenue NY rev (3m)4.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 79.88 | ||
| P/S | 1.43 | ||
| P/FCF | 208.79 | ||
| P/OCF | 16.67 | ||
| P/B | 0.77 | ||
| P/tB | 1.99 | ||
| EV/EBITDA | 12.39 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.07
Fwd EY1.25%
FCF(TTM)0.03
FCFY0.48%
OCF(TTM)0.36
OCFY6%
SpS4.17
BVpS7.72
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% | ||
| FCFM | 0.69% |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Debt/EBITDA | 1.93 | ||
| Cap/Depr | 58.99% | ||
| Cap/Sales | 7.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 80.91% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | 2.09 |
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
EPS Next Y-382.8%
EPS Next 2Y22.26%
EPS Next 3Y41.41%
EPS Next 5Y55.65%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
Revenue Next Year20.19%
Revenue Next 2Y14%
Revenue Next 3Y9.74%
Revenue Next 5Y10.5%
EBIT growth 1Y-395.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year455.38%
EBIT Next 3Y80.13%
EBIT Next 5Y56.34%
FCF growth 1Y-63.88%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y56.3%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA.
Can you provide the valuation status for KNIGHT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 2 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.
Can you provide the expected EPS growth for GUD stock?
The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to decline by -382.8% in the next year.